Analysis of Predictive and Preventive Factors for De Novo DSA in Kidney Transplant Recipients
Authors:
- 27 August 2014
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 98 (4) , 443-450
Abstract
Background Development of de novo donor-specific anti-HLA antibodies (dnDSA) has been associated with poor graft outcome, although the preventive factor for its production is still elusive. We analyzed the incidence of dnDSA within 5 years posttransplant in 562 living-kidney transplant recipients to evaluate predicting and preventive factors for dnDSA development. Materials and Methods All patients were considered to be non-HLA sensitized, as determined by the preoperative single-antigen bead assay (SABA), although they included various ABO blood type compatibilities. Preoperative administration of rituximab was indicated for 48% of patients, mainly for ABO incompatible transplantation. We retrospectively compared the patients with dnDSA and those without. Results Development of dnDSA was observed in 27 of the total 562 patients (5%). Chronic rejection was more frequently observed in patients with dnDSA than in those without (41% vs. 6%, PP=0.012) and patients with a higher number of HLA-DR mismatches (odds ratio 2.41, P=0.008), whereas lower likelihood was observed in patients treated with rituximab induction (odds ratio 0.33, P=0.040). Conclusion Results suggest that rituximab induction as a standard immunosuppression protocol may have a preventive effect for dnDSA production in the non-HLA sensitized low immunologic risk patients.Keywords
This publication has 38 references indexed in Scilit:
- De Novo Donor-Specific Antibody at the Time of Kidney Transplant Biopsy Associates with Microvascular Pathology and Late Graft FailureAmerican Journal of Transplantation, 2009
- Anti-Human Leukocyte Antigen and Donor-Specific Antibodies Detected by Luminex Posttransplant Serve as Biomarkers for Chronic Rejection of Renal AllograftsTransplantation, 2009
- Reducing De Novo Donor-Specific Antibody Levels during Acute Rejection Diminishes Renal Allograft LossAmerican Journal of Transplantation, 2009
- Poor graft outcome in recipients withde novodonor-specific anti-HLA antibodies after living related kidney transplantationTransplant International, 2008
- Post-Transplant Anti-HLA Class II Antibodies as Risk Factor for Late Kidney Allograft FailureAmerican Journal of Transplantation, 2006
- Frequency and Clinical Implications of Development of Donor-Specific and Non–Donor-Specific HLA Antibodies after Kidney TransplantationJournal of the American Society of Nephrology, 2005
- Prevalence and significance of anti-HLA and donor-specific antibodies long-term after renal transplantationTransplant International, 2005
- Predicting Kidney Graft Failure by HLA Antibodies: a Prospective TrialAmerican Journal of Transplantation, 2004
- Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome1Transplantation, 2003
- POSTTRANSPLANT ANTIDONOR LYMPHOCYTOTOXIC ANTIBODY PRODUCTION IN RELATION TO GRAFT OUTCOMETransplantation, 1987